These findings indicate that a rational multi-pathway inhibition strategy may offer a more efficacious approach for treating HR+/HER2+ breast cancer, potentially leading to improved clinical outcomes in this therapeutically challenging subgroup.14,15,18,20,22 Our comprehensive molecular analysis identified a synergistic mechanism for such multiple-pathway targeted blockade, providing a strong scientific rationale for the development of novel combination regimens that are specifically tailored to the unique biology of HR+/HER2+ disease.23 The gene discussed is ERBB2; the disease is breast carcinoma.